| scholarly article | Q13442814 |
| P50 | author | Mavis Agbandje-McKenna | Q28036887 |
| P2093 | author name string | Scott McPhee | |
| Chengwen Li | |||
| R Jude Samulski | |||
| Aravind Asokan | |||
| Shuqing Wu | |||
| Wuping Li | |||
| Matthew Hirsch | |||
| Yu-Shan Tseng | |||
| Blake Albright | |||
| P2860 | cites work | CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice | Q24286950 |
| Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus | Q24523073 | ||
| The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. | Q24533492 | ||
| Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration | Q24627838 | ||
| Safety and efficacy of gene transfer for Leber's congenital amaurosis | Q24634724 | ||
| Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20 | Q27681034 | ||
| Coot: model-building tools for molecular graphics | Q27860505 | ||
| Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions | Q27860532 | ||
| The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling | Q27860637 | ||
| MEGA5: Molecular Evolutionary Genetics Analysis Using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods | Q27860929 | ||
| Features and development of Coot | Q27861079 | ||
| Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial | Q28262431 | ||
| Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response | Q29619095 | ||
| Directed evolution of adeno-associated virus yields enhanced gene delivery vectors | Q33232270 | ||
| In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses | Q33327474 | ||
| Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles | Q33337378 | ||
| Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium | Q33482133 | ||
| Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). | Q33521174 | ||
| Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes | Q33793801 | ||
| Immune responses to adenovirus and adeno-associated virus in humans. | Q33874473 | ||
| AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. | Q34168942 | ||
| AAV capsid structure and cell interactions | Q34228175 | ||
| Empty Virions In AAV8 Vector Preparations Reduce Transduction Efficiency And May Cause Total Viral Particle Dose-Limiting Side-Effects | Q34632510 | ||
| Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector | Q34633598 | ||
| Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors | Q34938807 | ||
| Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. | Q35140088 | ||
| A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. | Q35568505 | ||
| Adenovirus-associated virus vector-mediated gene transfer in hemophilia B | Q35691659 | ||
| Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles | Q36171820 | ||
| Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue | Q36322970 | ||
| Kinetics of adeno-associated virus serotype 2 (AAV2) and AAV8 capsid antigen presentation in vivo are identical | Q36848699 | ||
| Capsid antibodies to different adeno-associated virus serotypes bind common regions. | Q37123344 | ||
| VIPERdb2: an enhanced and web API enabled relational database for structural virology | Q37202425 | ||
| Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy | Q37364038 | ||
| Selection and evaluation of clinically relevant AAV variants in a xenograft liver model | Q37610916 | ||
| Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia | Q39519818 | ||
| Gene therapy vectors based on adeno-associated virus type 1. | Q39550492 | ||
| Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure | Q39589248 | ||
| Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer | Q39603323 | ||
| Characterization of tissue tropism determinants of adeno-associated virus type 1. | Q39700318 | ||
| PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization | Q40413171 | ||
| Serotype-specific replicating AAV helper constructs increase recombinant AAV type 2 vector production | Q40436594 | ||
| Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors. | Q41318528 | ||
| Overcoming preexisting humoral immunity to AAV using capsid decoys | Q42056009 | ||
| Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization | Q42203239 | ||
| Efficient AAV1-AAV2 hybrid vector for gene therapy of hemophilia | Q42252699 | ||
| Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice | Q43847196 | ||
| Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors | Q44258968 | ||
| Epidemiology of adenovirus-associated virus infection in a nursery population | Q44631695 | ||
| Coating of adeno-associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera | Q45397577 | ||
| Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults | Q45409947 | ||
| Combinatorial engineering of a gene therapy vector: directed evolution of adeno-associated virus | Q45422552 | ||
| Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. | Q45571369 | ||
| Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies | Q45709087 | ||
| Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). | Q45747007 | ||
| Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice | Q45858191 | ||
| Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors | Q45873434 | ||
| Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. | Q45882349 | ||
| Utility of PEGylated recombinant adeno-associated viruses for gene transfer. | Q46672745 | ||
| Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological Nanoparticles | Q56897778 | ||
| Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus | Q64380675 | ||
| P433 | issue | 1 | |
| P921 | main subject | antibody | Q79460 |
| patient | Q181600 | ||
| P304 | page(s) | 53-65 | |
| P577 | publication date | 2015-07-29 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | Development of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene Transfer | |
| P478 | volume | 24 |
| Q57562597 | AAVvector-mediated in vivo reprogramming into pluripotency |
| Q38645275 | Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion |
| Q99559716 | Bound Protein and Peptide-Based Strategies for Adeno-associated Virus Vector-Mediated Gene Therapy: Where do We Stand Now? |
| Q97423868 | Development of AAV Variants with Human Hepatocyte Tropism and Neutralizing Antibody Escape Capacity |
| Q89637735 | Engineering adeno-associated virus vectors for gene therapy |
| Q91936196 | Engineering the AAV capsid to evade immune responses |
| Q40212331 | Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies |
| Q39465145 | High-Density Recombinant Adeno-Associated Viral Particles are Competent Vectors for In Vivo Transduction |
| Q45873745 | Immunity to CRISPR Cas9 and Cas12a therapeutics |
| Q47553772 | In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease |
| Q88166600 | Liver induced transgene tolerance with AAV vectors |
| Q55364362 | Nab Escaping AAV Mutants Isolated from Mouse Muscles. |
| Q99561220 | Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme |
| Q39122342 | Seek and destroy: targeted adeno-associated viruses for gene delivery to hepatocellular carcinoma. |
| Q38908933 | Systemic delivery of adeno-associated viral vectors |
| Q45874356 | Viral Vectors, Engineered Cells and the CRISPR Revolution |
Search more.